Immedica Pharma Ab
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.immedica.com
Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
5
EMA:4
NMPA:1
Drug Approvals
Glycerol Phenylbutyrate Oral Liquid
- Product Name
- 口服用苯丁酸甘油酯
- Approval Number
- 国药准字HJ20230071
- Approval Date
- Jul 10, 2023
NMPA
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Immedica Pharma AB
- Target Recruit Count
- 3
- Registration Number
- NCT06582524
- Locations
- 🇦🇹
Univ. Klinik für Kinder- und Jugendheilkunde Medizinische Universität, Graz, Austria
🇵🇹Unidade de Doenças Metabólicas Pediatria, Hospital Santa Maria, Lisboa, Portugal
🇬🇧Bradford Royal Infirmary Duckworth Lane, Bradford, United Kingdom
News
Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million
Ovid Therapeutics has entered into a definitive agreement with Immedica Pharma AB to sell its future royalty rights for ganaxolone sales outside China for $7 million in cash.
Aeglea BioTherapeutics Submits BLA for Pegzilarginase as First Potential Treatment for Arginase 1 Deficiency
Aeglea BioTherapeutics has submitted a Biologics License Application to the FDA for pegzilarginase with Priority Review request, potentially becoming the first approved treatment for Arginase 1 Deficiency.